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Abstract
Background: Several uterotonic options exist for prevention of postpartum hemorrhage 
(PPH); hence, cost- effectiveness is an important decision- making criterion affecting 
uterotonic choice.
Objective: To conduct a systematic review of cost- effectiveness of uterotonics for PPH 
prevention to support a WHO guideline update.
Search strategy: We searched major databases from 1980 to June 2018 and the 
National Health Services Economic Evaluation (NHS EED) database from inception 
(1995) to March 2015 for eligible studies.
Selection criteria: We included comparative economic evaluations, cost- utility analyses, 
and resource- utilization studies.
Data collection and analysis: Two reviewers independently assessed studies and 
extracted data organized by birth mode and setting.
Main results: We included 15 studies across all income categories that compared mis-
oprostol versus no uterotonic (five studies) or versus oxytocin (one study), carbetocin 
versus oxytocin (eight studies), and one study comparing numerous uterotonics. In spe-
cific low- resource contexts, we found reasonably good evidence that misoprostol was 
cost- effective compared with no uterotonic. In the context of cesarean delivery, car-
betocin was more cost favorable than oxytocin but certainty of this evidence was low.
Conclusions: Evidence on the cost- effectiveness of various uterotonic agents was not 
generalizable. As the number of competing uterotonics increases, rigorous economic 
evaluations including contextual factors are needed.
K E Y W O R D S
Carbetocin; Cost-effectiveness; Ergometrine; Misoprostol; Oxytocin; Postpartum hemorrhage; 
Prostaglandins; Uterotonics
1  | INTRODUCTION
Postpartum hemorrhage (PPH) is generally defined as blood loss of 
500 mL or more within 24 hours after birth and affects around 5% of 
women giving birth globally.1,2 It is most often caused by failure of the 
uterus to contract after childbirth.3 Pre- existing WHO guidance on 
PPH prevention recommends that all women giving birth are routinely 
offered an effective uterotonic agent during the third stage of labor.4
This is an open access article distributed under the terms of the Creative Commons Attribution IGO License which permits unrestricted use, distribution and 
reproduction in any medium, provided that the original work is properly cited. In any reproduction of this article there should not be any suggestion that WHO or the 
article endorse any specific organization or products. The use of the WHO logo is not permitted. This notice should be preserved along with the article’s URL.
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There are several uterotonic agents that are in clinical use or that 
have been evaluated for PPH prevention, including oxytocin, car-
betocin, ergometrine, misoprostol, injectable prostaglandins (such 
as sulprostone and carboprost), as well as the combination agent 
Syntometrine (ergometrine plus oxytocin) (Alliance Pharma plc, 
Chippenham, UK) (Table 1). However, many settings (particularly low- 
resource settings) often do not have all uterotonic agents available. 
Since 2012, WHO has recommended oxytocin as the uterotonic of 
choice to prevent PPH.4 In settings where oxytocin is not available, 
other uterotonics (ergometrine, ergometrine and oxytocin, or miso-
prostol) are the alternatives recommended by WHO.
When health systems’ stakeholders consider which uterotonic 
option should be used in their context, consideration is given to a 
number of factors, including efficacy and safety, how feasible and 
acceptable the option is, whether it is cost- effective, and the resources 
required to provide it. The cost- effectiveness of a uterotonic option 
may differ depending on the mode of birth (vaginal birth or cesarean 
delivery) or birth setting (hospitals vs community settings) and, in the-
ory, a high unit cost of a uterotonic option might potentially be offset 
by cost savings associated with a reduction in adverse outcomes.
While some studies have assessed cost- effectiveness of a sin-
gle uterotonic in a specific setting, to our knowledge, no system-
atic review has been conducted to identify and assess the available 
economic evaluation evidence for all uterotonic options when used 
for PPH prevention. This review was performed in the context of 
an evidence base preparation to update WHO's recommendations 
on uterotonics for PPH prevention.10 The review aimed to summa-
rize the available evidence on the cost- effectiveness of uterotonic 
agents when applied for the prevention of PPH. Additionally, we 
evaluated available evidence regarding which uterotonic agents are 
cost- effective to prevent PPH according to mode of birth (vaginal 
birth or cesarean delivery), and birth settings (community settings 
without skilled birth attendants, and in hospital settings where 
injectable uterotonic is not available).
2  | MATERIALS AND METHODS
2.1 | Literature search
We searched Medline (1980 to May week 4 2018), Embase (1980 to 
week 22 2018), and the National Health Services Economic Evaluation 
(NHS EED) database from inception in 1995 to 2 April 2015 (data-
base closure) for studies evaluating costs and cost- effectiveness of 
any uterotonic agent, alone or in combination, in comparison with 
oxytocin, placebo, or another uterotonic agent used for the primary 
prevention of PPH in women in the third stage of labour in any setting 
(community, healthcare centre, or hospital).
2.2 | Data extraction and quality assessment
Cochrane methodology for economic evaluations was used.11 Two 
researchers (TL and ER) independently assessed for inclusion all 
potentially eligible studies. Any disagreements were resolved through 
discussion or by consulting a third author. A data extraction form was 
adapted from the guidance for NHS EED abstracts of economic evalu-
ations.12 For each included study, two authors independently extracted 
information on type of cost evaluation (study design), sources of 
effectiveness data, type of costs and their source, sources of outcome 
valuations, and type of adopted analytical approach. Where available, 
Incremental Cost- Effectiveness Ratios (ICERs) were extracted (an ICER 
is the ratio of the difference in costs between an intervention or treat-
ment and a specified comparator to the difference in effectiveness or 
outcome between that intervention and the specified comparator). 
Quality of identified studies was systematically evaluated using the 
Consensus Health Economic Criteria (CHEC) checklist.13 Assessments 
were compared and disagreements resolved through discussion or con-
sulting a third author.
2.3 | Data synthesis
We developed a conceptual framework on the possible cost conse-
quences associated with use of a uterotonic agent to prevent PPH (Fig. 1). 
For identified studies, we tabulated the characteristics and findings of 
individual economic evaluations and supplemented it with a brief narra-
tive summary of the findings. The currency and price year applicable to 
measures of costs in each original study were reported alongside meas-
ures of costs, incremental costs, and incremental cost- effectiveness. 
Findings were summarized according to mode of birth (vaginal birth or 
cesarean delivery) and birth setting (hospital or community).
3  | RESULTS
3.1 | Characteristics of included studies
The combined deduplicated search yield was 180 records. We addi-
tionally identified two records (one conference abstract and one com-
missioned report) through searching the reference lists of included 
papers. Out of 182 retrieved citations, 168 studies were assessed as 
irrelevant on title and abstract screening and nine full text retrievals 
contained no cost- effectiveness data, leaving 15 studies that met the 
eligibility criteria of this review (Fig. 2). One unpublished report identi-
fied in the reference list of an included study could not be retrieved: 
two were conference abstracts and contained limited data.14,15
Included studies were conducted in Columbia,15 Ecuador,16 
India,17,18 Malaysia,19 Mexico.14 Peru,20 Senegal,21 Tanzania,22 
Uganda,23 and the UK.24–27 One of the studies was an international 
study with a hypothetical cohort.28 Eleven of these studies were con-
ducted from 2011 to 2018 and four studies were conducted from 2007 
to 2010.14,17,18,22 Out of the 15 studies, three studies were funded by 
pharmaceutical companies,16,20,27 six studies were funded by orga-
nizations and institutions, such as WHO, the Bill and Melinda Gates 
Foundation, Department for International Development, National 
Institute for Health Research, and others,17,18,21,22,24,28 three stud-
ies were not funded,23,25,26 in two studies (abstracts) it was unclear 
whether they were funded or not,14,15 and one study did not disclose 
funding sources.19
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The relevant healthcare perspective was used in all studies except 
in one study, which adopted a WHO perspective. A majority of the 
studies were model- based, using decision analytical models (deci-
sion trees), with the exception of two studies that used data directly 
obtained from randomized controlled trials,14,21 one observational 
study,25 and a service composite clinical and financial analysis study.27 
Various measures (condition- specific and generic) were used to mea-
sure health outcome of uterotonics including incidence and cases of 
PPH, use of additional uterotonics, mortality, probability of mortality, 
referral to higher- level health facility, adverse effects, quality- adjusted 
life years (QALYs), and disability- adjusted life years (DALYs). One 
study was a cost- effectiveness analysis of several uterotonics based 
on a network meta- analysis (NMA) adopting a UK perspective.24 Six 
studies evaluated the cost- effectiveness of misoprostol versus third 
stage management without any uterotonics (five studies) or oxy-
tocin (one study), all of which were conducted in settings with low 
access to facility births.17,18,21–23,28 A further eight studies evaluated 
the  cost- effectiveness of carbetocin versus oxytocin across various 
facility settings.14–16,19,20,24–26
3.2 | Which uterotonic agents are cost- effective for 
preventing PPH at vaginal birth?
One study based on the UK health service perspective provided evi-
dence on this question. The study was a cost- effectiveness analysis 
conducted as part of a systematic review and NMA that compared the 
different uterotonics and ranked them according to cost and effec-
tiveness (conducted as part of a UK health technology assessment).24 
When adverse events were considered, oxytocin (which ranked fourth 
in effectiveness) was the least costly uterotonic agent. Compared with 
oxytocin, carbetocin (which ranked as a more effective agent) was 
associated with an ICER of approximately US $1193.58 per additional 
PPH of greater than or equal to 500 mL avoided, and US $29 464.19 
per additional PPH greater than or equal to 1000 mL avoided. These 
findings were similar for hospital and community settings in the UK. 
Misoprostol was found to be the costliest uterotonic agent in this set-
ting when adverse events were considered.
3.3 | Which uterotonic agents are cost- effective for 
preventing PPH at cesarean delivery?
Eight cost- effectiveness analyses and one service evaluation study 
contributed data.14–16,19,20,24–27 Four were from a high- income coun-
try (UK) and five were from middle- income countries (Columbia, 
Ecuador, Malaysia, Mexico, and Peru). Apart from the UK- based study 
that evaluated several uterotonic options,24 all studies compared 
carbetocin (100 μg) to oxytocin (5 or 10 IU, if dose was reported). 
Four studies based their cost- effectiveness analysis on effectiveness 
outcome data of a published Cochrane systematic review of carbe-
tocin for preventing PPH,16,19,20,26 three evaluations were based on 
prospective studies,14,25,27 one on the findings of the NMA,24 and the 
source of the effectiveness data in one study reported as a conference 
abstract was unclear.15
In the UK cost- effectiveness analysis that compared various utero-
tonic options,24 data on costs for adverse events (considered in this 
model to be nausea, vomiting, hypertension, headache, tachycardia, 
shivering, and fever) were described by investigators as very uncertain. 
However, when these were considered, carbetocin was associated 
with lower costs relative to the next most cost- effective option—the 
misoprostol plus oxytocin combination. The ICER for averting one 
case of PPH greater than or equal to 1000 mL in the UK context was 
reported as approximately US $2927.30 with carbetocin versus the 
misoprostol plus oxytocin combination, and averting a major adverse 
outcome was US $114 347.78. However, when adverse events were 
not considered, the misoprostol plus oxytocin combination was found 
to be more cost- effective than carbetocin. In these analyses, these 
two uterotonic options (i.e. carbetocin or misoprostol plus oxytocin) 
were both more cost- effective than misoprostol or oxytocin alone.
The eight other studies that evaluated economic outcomes asso-
ciated with carbetocin at cesarean delivery all compared carbetocin 
F IGURE  1 Diagram of possible consequences associated with use of a uterotonic agent.
Increasing costs
Birth of baby Uteronic agentadministered
PPH prevented without
uterotonic adverse
effects
PPH prevented, but
with uterotonic adverse
effects
Treatment of adverse
effects with or without
higher staff and
facility/bed costs
PPH not prevented
(with or without
adverse effects)
Additional uterotonic
agent/s administered;
potentially higher staff
and facility/bed costs
Severe PPH not averted
Further costly interventions
required, such as balloon
tamponade, blood
transfusion, postpartum
surgery with higher staff and
facility/bed costs
Severe PPH averted
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(100 μg) to oxytocin (5 or 10 IU, where dose was reported). Seven 
studies concluded that carbetocin was cost- effective at cesarean 
delivery compared with oxytocin.14–16,19,20,25,26 However, in some 
of these studies19,20,26 investigators reported that uncertainty 
around costs and other input data made it difficult to evaluate cost- 
effectiveness with any certainty. We considered the quality of the 
evidence provided by these studies to be low, owing to a lack of sen-
sitivity analyses and incomplete description of the methods of out-
come and costs measurements in most studies. In addition, at least 
two of the studies from middle- income countries favoring carbeto-
cin were funded by the manufacturer and, as such, we interpreted 
findings from these studies and those of the conference abstracts 
with limited data14,15 cautiously owing to the potential risk of bias 
and imprecision.
In the remaining study, a UK service evaluation study,27 investi-
gators reported a significant increase in the cost of care during the 
period from birth of baby to transfer to the postnatal ward of low- risk 
women undergoing elective cesarean delivery (from approximately 
US $104.27 before the introduction of carbetocin, to US $128.35 fol-
lowing this (P<0.01), but economic modelling was not performed in 
this study.
3.4 | Uterotonic agents in community settings 
without skilled birth attendants
The cost- effectiveness of misoprostol was evaluated in settings 
with low access to modern birth facilities (lack of skilled birth 
attendants, inadequate transport and storage facilities, or oxy-
tocin not available) in six studies.17,18,21–23,28 These studies were 
of moderate to high quality according to the CHEC checklist,13 
and most used a model- based approach to estimate incremental 
costs of introducing misoprostol to prevent PPH in these settings. 
Four studies evaluated misoprostol as a 600- μg dose (oral or sub-
lingual),17,18,21,23 one used a 200- μg dose,28 and one used a 1000- 
μg dose rectally administered.22 In most studies administration of 
misoprostol was undertaken by lay health workers; in one study in 
Uganda it was distributed prenatally to pregnant women for self- 
administration following birth.23 Although cost- effectiveness meas-
ures and reporting differed (e.g. ICER per case of PPH avoided, per 
DALY gained, per life saved, cost savings per 1000 births, etc.), 
findings across studies consistently showed that misoprostol was 
highly cost- effective (or led to cost savings) compared to no utero-
tonic agents in these settings. A study from Senegal,21 found mis-
oprostol (600 μg orally) to be more cost- effective than oxytocin 
(10 IU provided via the Uniject system; BD Company, Franklin 
Lakes, NJ, USA) in rural settings; it should be noted that the finding 
may be driven mainly by the lower cost of misoprostol. Oxytocin 
was assumed to have higher wastage costs based on a rate derived 
from a randomized trial in which 12.1% of oxytocin Uniject devices 
were discarded owing to breakage, being compromised by heat, or 
having passed the expiration date.29
3.5 | Uterotonic agents in hospital settings where 
oxytocin quality cannot be guaranteed
We found no research evidence that directly addresses this question. 
However, in the UK NMA cost- effectiveness analysis, if the option of 
oxytocin alone or in combination with other agents was removed from 
the study analyses, findings suggest that carbetocin might be the most 
cost- effective uterotonic for vaginal birth (and cesarean delivery) in 
the UK context, followed by ergometrine (if adverse events were 
considered), or misoprostol (if adverse events were not considered). 
These findings were uncertain and might not be generalizable to other 
settings, particularly settings where injectable uterotonics cannot 
be used.
4  | DISCUSSION
Cost- effectiveness studies on PPH prevention in different contexts 
were sparse given the range of uterotonic agents available. We found 
F I G U R E  2 Flow diagram of search results and study selection.
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reasonable quality evidence that misoprostol compared with no uter-
otonic agent was cost- effective for preventing PPH at vaginal birth 
in settings with low access to modern birth facilities. With regard to 
preventing PPH at cesarean delivery, the evidence suggested that 
carbetocin might be more cost- effective than oxytocin, and that the 
next most cost- effective option after carbetocin might be the com-
bination of misoprostol and oxytocin; however, these findings were 
fairly uncertain.
To our knowledge this is the only systematic review of the cost- 
effectiveness of uterotonic agents for PPH prevention to date. We 
used a broad, systematic search to identify potentially eligible stud-
ies, and we were guided by principles and methods of the Cochrane 
Handbook and the NHS EED. Unfortunately, review findings were 
often uncertain owing to methodological limitations and the qual-
ity of reporting in the included studies. For vaginal birth, we found 
only two studies comparing cost- effectiveness of one uterotonic 
option with another uterotonic option, and no studies comparing 
cost- effectiveness of multiple uterotonics in low- and middle- income 
(LMIC) country settings.
Another limitation is that the evidence derived from a rigorous 
cost- effectiveness analysis conducted in the UK that compared vari-
ous uterotonic options with each other was probably not generalizable 
to many other countries. While this study obtained a high score on the 
CHEC checklist,13 input cost data (such as bed, staff, and intervention 
costs) are likely to be considerably different in LMICs. In addition, in 
this study, misoprostol was associated with higher costs, which were 
derived from longer bed stays and unnecessary tests related to its 
common adverse effects (shivering and fever); such costs might be 
negligible in LMIC settings, owing to expectant management of these 
adverse effects and lower bed costs.
Heat- stable uterotonics that do not require refrigeration (such as 
misoprostol and the heat- stable formulation of carbetocin) can offer 
advantages for low- resource settings with no or limited access to cold 
chain transport and storage. While the evidence suggests that miso-
prostol is cost- effective in these settings, little is known about the 
cost- effectiveness of carbetocin in this context or its relative cost- 
effectiveness compared with other options for vaginal birth in different 
settings. It should be noted that carbetocin requires a trained, skilled 
health provider to administer it parenterally, whereas misoprostol can 
be administered orally by lower cadres of health workers (such as com-
munity health workers or lay health workers). In addition, as the price 
of the uterotonic agent appears to be critical to costing models for low- 
resource settings (more so than for high- resource setting models), the 
cost- effectiveness of carbetocin relative to misoprostol will be strongly 
affected by the supply prices. While the price range across studies 
included in the review was US $13.10–25.60 per 100- μg carbetocin 
dose, compared with US $0.27–1.56 for a 600- μg misoprostol dose, 
we note that the manufacturer of heat- stable carbetocin has made an 
in- principle commitment to make the heat- stable formulation of car-
betocin available in the public sector of LMICs at an affordable and sus-
tainable price, comparable to the UNFPA price of oxytocin (US $0.27).30
This study is a systematic review of available formal economic 
analyses of uterotonics agents but is itself not an economic evaluation 
or analysis. Findings from our review highlight the lack of reliable evi-
dence on the cost- effectiveness of these agents in different settings, 
and hence a well- conducted economic evaluation of all agents (par-
ticularly in low- resource settings) is needed. Such an analysis would 
serve as an important guide to decision and policy making in PPH pre-
vention, particularly in LMICs.
Given the paucity of available evidence on uterotonic cost- 
effectiveness, for the purposes of informing the WHO guideline 
update process, we created a logic model on cost- effectiveness con-
siderations across the different uterotonic options to aid decision 
makers and other stakeholders (Table 2). In this approach, we used 
up- to- date evidence on the relative effectiveness and safety of the 
different uterotonic agents relative to oxytocin from an updated 
Cochrane systematic review and NMA.31 We tabulated the risk ratios 
of desirable and undesirable effects. In addition, we tabulated their 
potential cost consequences relative to oxytocin, including resource 
requirements related to staffing and training, equipment and infra-
structure, staff time, supplies, and supervision and monitoring that are 
associated with these options (Table 2). For uterotonic supply prices, 
we referenced costs from the British National Formulary,32 which 
served to illustrate relative drug costs in a setting where all agents 
were available. The intention of the logic model was to facilitate a sys-
tematic, qualitative assessment of resource use and cost- effectiveness 
factors across the different uterotonic options in the absence of good 
evidence of the relative cost- effectiveness of available uterotonics in 
different contexts.
In conclusion, evidence on the cost- effectiveness of various 
uterotonic agents is sparse and largely not generalizable to differ-
ent contexts. In the absence of reliable evidence, it is likely that the 
choice of uterotonic will be highly influenced by uterotonic price, 
as well as contextual factors. In view of the increasing number of 
competing uterotonics, more rigorous economic evaluations based 
on robust efficacy evidence and considerations of contextual factors 
are needed.
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